Projects

MEPHITIS

project name: Targeting Protein Synthesis in the Apicoplast and Cytoplasm of Plasmodium

initiating country: The European Union

Framework Programme: FP7       programme area: Health       contract type: CP-SICA – Collaborative Project (SICA)

contract/proposal/call number: 223024

status: active

start date: January 2009       duration: 36 months       projected finish date: January 2012

Keywords

keywords: HIV AIDS malaria

Project Budget

total budget: € 3,342,251

Participants

Note that the follow people may not represent the full extent of the consortium. FEAST has tried to identify the Australian participants, and their collaborators (or coordinator), within the project. Also note that Australian participation may not necessarily be on a formal level.

nameorganisationstate or country
Dr Lluis Ribas De PouplanaIRB Spain
Dr Stuart RalphThe University of Melbourne VIC, Australia
CNRS France

Further information

summary:
  Highly innovative research in HIV/AIDS, malaria and tuberculosis between Indian and European partners
 
  The protein synthesis machinery represents one of the most useful targets for the development of new anti-infectives. Several families of broadly used antibiotics (tetracyclines, macrolides, and novel glycopeptides like vancomycin, among others) exert their function by blocking the protein synthesis machinery. Doxicycline, a tetracycline antibiotic, remains a useful tool for the prevention of paludism among travellers, despite its numerous secondary effects. And yet, very little is known about the specifics of the protein synthesis machinery in Plasmodium. A search of articles in the PubMed library with the words Plasmodium and ribosome/ribosomal in their titles will yield 6 publications since the year 2000.
 
  Only one article contains the words tRNA (or transfer RNA) and Plasmodium in its title, in the same period. And only one article in PubMed (Snewin et al., 1996) contains the words Plasmodium and tRNA synthetase (or ligase) in its title. This lack of information about this central metabolic pathway in Plasmodium clearly blocks the possibility of transferring the knowledge in protein synthesis to the development of new anti-malarial drugs directed against the translational machinery of the parasite. Thus, the study of components of the genetic code in Plasmodium has the potential for providing new and important information on the biology of the parasite and, more importantly, open new leads for the development of novel anti-malarials.
 
  This proposal coordinates an effort to study tRNA biology in Plasmodium falciparum. It contains specific schemes for the development of new pharmacological screens, several initiatives for the selection of new potential anti-malarial drugs, and projects designed to answer fundamental questions regarding protein synthesis in Plasmodium. The laboratories in MEPHITIS accumulate a large body of experience in the biology of this parasite, and in different aspects of tRNA biology in model species.
 
  Participants
  COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH INDIA
  UNIVERSITY OF MELBOURNE AUSTRALIA
  FUNDACIO PRIVADA PARC CIENTIFIC DE BARCELONA SPAIN
  INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY ITALY
  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) FRANCE
  ISTITUTO SUPERIORE DI SANITA ITALY
  UNIVERSIDADE DE AVEIRO PORTUGAL
 
  Source: Cordis